Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best biotech stocks with high potential. On October 1, Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) and set a price target of $90.00.

Is Crinetics Pharmaceuticals Inc. (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

In other news, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced the FDA approval of PALSONIFYTM (paltusotine) as a “first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option” on September 25.

PALSONIFY is a selectively-targeted somatostatin receptor type 2 nonpeptide (SST2) agonist, and management stated that the FDA approval makes it the first once-daily, oral treatment approved for acromegaly in adults.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics for rare endocrine diseases and endocrine-related tumors.

The company’s product candidate, CRN00808, is an oral treatment for acromegaly. It is also developing other oral treatments for neuroendocrine tumors, hyperinsulinism, and Cushing’s disease.

While we acknowledge the potential of CRNX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRNX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.